Real-world Data on Voclosporin for the Treatment of Lupus Nephritis Including Use of Concomitant Biologic Therapies: An Analysis of the Enlight-LN Registry Assistant Clinical Professor of Medicine and Director of Nephrology Fellowship Program (UKKW 2026) - Mar 16, 2026 - Abstract #THK7; Pres time: Mar 12, 2026; 10:00 AM - 11:00 AM; Location: HALL Q; P | "In the Phase 3 AURORA studies, voclosporin plus Mycophenolate Mofetil (MMF) and low-dose glucocorticoids led to significant reductions in proteinuria while maintaining a stable eGFR for up to 3 years of follow-up...There were 83 (36.2%) patients on voclosporin who concomitantly received treatment with a biologic including belimumab (28.4%), rituximab (4.8%), anifrolumab (3.9%) and obinutuzumab (1.3%)... As of April 4, 2025, data were available on 229 patients. Median (range) patient age was 34.0 (18–78), with 36.2% of patients ≤30 years; 83.4% were female. Most patients self- identified as White (43.2%) or Black/African American (38.0%); 35.4% were Hispanic/Latino."
Clinical • Real-world • Real-world evidence • Glomerulonephritis • Immunology • Inflammatory Arthritis • Lupus • Lupus Nephritis • Nephrology • Renal Disease • Systemic Lupus Erythematosus
|
|
Kamgar Mohammad1; Assistant Clinical Professor of Medicine and Nephrologist Nobakht Niloofar1; Associate Professor of Medicine and Rheumatologist Geraldino-Pardilla Laura B.2; Assistant Professor of Clinical Medicine Wise Leanna M.3; Associate Director, Clinical Development Rosales Amber4; Senior Manager, Clinical Operations McIntosh Barbara4; Sadiq Ahmed, Senior Director, Medical Affairs Flauto Ronald P.4
|